You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

Dr Reddys Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for DR REDDYS, and when can generic versions of DR REDDYS drugs launch?

DR REDDYS has three hundred and sixty approved drugs.

There are two US patents protecting DR REDDYS drugs. There are twenty tentative approvals on DR REDDYS drugs.

There is one patent family member on DR REDDYS drugs in one country and seven hundred and fifty supplementary protection certificates in eighteen countries.

Summary for Dr Reddys
International Patents:1
US Patents:2
Tradenames:289
Ingredients:262
NDAs:360

Drugs and US Patents for Dr Reddys

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys FEBUXOSTAT febuxostat TABLET;ORAL 205374-002 Oct 22, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys ATORVASTATIN CALCIUM atorvastatin calcium TABLET;ORAL 214659-002 Jul 14, 2021 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys BORTEZOMIB bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 202963-001 Jul 26, 2022 AP RX No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys NALBUPHINE HYDROCHLORIDE nalbuphine hydrochloride INJECTABLE;INJECTION 074471-002 Mar 19, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys Labs Sa CLOZAPINE clozapine TABLET;ORAL 203807-003 Aug 22, 2017 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys Labs Ltd ZENATANE isotretinoin CAPSULE;ORAL 202099-003 Mar 25, 2013 AB1 RX No No ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys Labs Sa TRIMETHOPRIM trimethoprim TABLET;ORAL 018679-001 Jul 30, 1982 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Dr Reddys

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-004 Nov 12, 1999 5,834,011 ⤷  Try a Trial
Dr Reddys Labs Sa TRI-NORINYL 28-DAY ethinyl estradiol; norethindrone TABLET;ORAL-28 018977-002 Apr 13, 1984 4,390,531 ⤷  Try a Trial
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-006 Nov 12, 1999 4,597,961 ⤷  Try a Trial
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-004 Nov 12, 1999 4,597,961 ⤷  Try a Trial
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-005 Nov 12, 1999 5,834,011 ⤷  Try a Trial
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-005 Nov 12, 1999 5,016,652 ⤷  Try a Trial
Dr Reddys Labs Sa HABITROL nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020076-004 Nov 12, 1999 5,016,652 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for DR REDDYS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Supplementary Protection Certificates for Dr Reddys Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1635783 C300653 Netherlands ⤷  Try a Trial PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
2701720 23C1000 France ⤷  Try a Trial PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
1685839 92292 Luxembourg ⤷  Try a Trial PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1255752 91407 Luxembourg ⤷  Try a Trial PRODUCT NAME: SUNITINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE SEL L-MALATE (SUTENT ); AUTHORISATION NUMBER AND DATE: EU/1/06/347/001-003 - SUTENT-SUNITINIB 20060724
0764174 SPC/GB04/031 United Kingdom ⤷  Try a Trial PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310
2962690 C 2019 032 Romania ⤷  Try a Trial PRODUCT NAME: APREMILAST SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/14/981; DATE OF NATIONAL AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/981; DATE OF FIRST AUTHORISATION IN EEA: 20150115
0489070 22/2004 Austria ⤷  Try a Trial PRODUCT NAME: BIVALIRUDIN UND TRIFLUORACETAT DAVON; REGISTRATION NO/DATE: EU/1/04/289/001 20040920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.